Sai Parenteral's Ltd. (Mainboard)

Mainboard
  1. Home
  2. Sai Parenteral's Ltd. (Mainboard)
Sai Parenteral's Ltd. (Mainboard)

Sai Parenteral's

Mainboard

Mar 24, 2026 – Mar 27, 2026

Price
₹372 – ₹392
GMP Rumors *
₹0
Lot Size
38
Issue Size
₹408.79 cr
Allotment
Mar 30, 2026
Listing
Apr 2, 2026
DHRP/RHP Anchor BOA Capital Structure
* info is indicative, not an investment advice.

Login to view

Login

Live Rate

Open
High
Low
Prev. Close
Lower circuit
Upper circuit
52w High
52w Low
P/E Ratio
*Source NSE/BSE

Sai Parenteral's Listing Price

Exchange Listing Price Gain/Loss %
NSE ₹400.00 +₹8.00 +2.04%
BSE ₹405.00 +₹13.00 +3.32%
*Source NSE/BSE

Login to view

Login

Shareholding Pattern

*Source NSE/BSE

Sai Parenteral's Subscription

Last updated on 27-Mar-2026 17:04:06

CategoryOfferedAppliedTimes
QIBs208565936102661.73
HNIs156424338315022.45
 HNIs 10+104282937073183.56
 HNIs 2+5214141241840.24
Retail36499014392040.12
Total729980378809721.08
Application-Wise Breakup (Approx. no. of Apps)img
CategoryReservedAppliedTimes
HNIs (10L+)19601600.08
HNIs (2-10L)9801270.13
Retail9605076510.08
Total Applications: 7938
© IPO Premium
Subscription Demand (in ₹ crore)
CategoryOfferedDemandTimes
QIBs81.76141.521.73
FIIs-72.53-
DIIs-20-
Mutual funds-30-
Others-19-
HNIs61.32150.192.45
HNIs 10+40.88145.333.56
HNIs 2+20.444.870.24
Retail143.0817.220.12
Total286.15308.931.08
QIB Interest Cost per share (7 Days)
@7%
₹0.9		@8%
₹1		@9%
₹1.2		@10%
₹1.3		@11%
₹1.4		@12%
₹1.6

Sai Parenteral's Lot(s) Distribution

Category Lot(s) Qty Amount Reserved
Retail 1 38 14896 96050
sHNI 14 532 208544 980
bHNI 68 2584 1012928 1960

Sai Parenteral's Reservation

Category Shares Offered %
Anchor 3128485 30%
QIB 2085659 20%
HNI 1564243 15%
Retail 3649901 35%
Total 10428288 100%

Sai Parenteral's About

IPO Details
Total Issue Size1,04,28,288 shares (aggregating up to ₹408.79 Cr)
Fresh Issue7,270,408 shares (aggregating up to ₹285  Cr)
Offer For Sale3,157,880 shares (aggregating up to ₹123.79  Cr)
Face Value₹5/- Per Share
Issue TypeBookbuilding IPO
Listing AtNSE ,BSE
Share Holding Pre Issue36,908,823 Shares
Share Holding Post Issue

4,41,79,231 shares

Key Performance Indicators (KPI)
KPISep-25Mar-25Mar-24Mar-23
RONE5.09%15.09%11.01%13.90%
ROCE9.28%28.92%20.52%21.04%
EPS (BASIC)2.826.1610.545.43
P/E Pre IPO72.19
 
Company Financial (In ₹Crore) 
Period EndedSep-25Mar-25Mar-24Mar-23
Assets376.24272.39268.1133.96
Total Income89.43163.74155.1897.03
Profit After Tax7.7614.438.424.38
EBITDA16.2439.4431.717.64
NET Worth209.3795.7876.431.49
Reserves and Surplus188.8480.3661.324.34
Total Borrowing76.0793.95118.7968.55
Peer Comparision (Valuation)
CompanyP/E (x)CMP*(₹)Face value (₹)
Sai Parenteral's72.19392.005.00
Sai Life Sciences Limited107.70879.151.00
Innova Captab Limited32.45727.2010.00
Senores Pharmaceutic als Limited64.3817.6510.00
Gland Pharma Limited44.711895.701.00
SOURCE:RHP,Price/earnings ratio for the peer group has been computed based on the closing market price of equity shares on BSE/NSE as on February 03, 2026, divided by the diluted earnings per share for the Fiscal 2025. we have shown the P/E ratio of the IPO issuer company based on the pre-IPO valuation, and the CMP has been represented by the IPO issue price (upper price band).

Peer Comparision (Financial Performance)
CompanyNAV/Share (₹)RoNW (%)EPS (Basic) (₹)
Sai Parenteral's35.9815.095.43
Sai Life Sciences Limited102.127.998.83
Innova Captab Limited167.6613.3722.41
Senores Pharmaceutic als Limited176.377.1816.12
Gland Pharma Limited555.417.6342.40
About Company

Sai Parenterals Limited, established in 1989, is a diversified pharmaceutical formulations company engaged in research, development, and manufacturing of a wide range of healthcare products. The Company operates through two key business verticals: Branded Generic Formulations and Contract Development & Manufacturing Organisation (CDMO) services.

Business Segments

Branded Generic Formulations:
The Company serves a broad domestic customer base, including government agencies (central and state), pharmaceutical companies, institutions, and super stockists.

CDMO Services:
Provides end-to-end solutions such as product development, regulatory dossier preparation, international filings, validation batches, and commercial-scale manufacturing.

Product Portfolio

Sai Parenterals offers a diverse portfolio of 100+ products across multiple therapeutic areas including:

  • Cardiovascular

  • Neuropsychiatry

  • Anti-diabetic

  • Respiratory

  • Antibiotics

  • Gastroenterology

  • Vitamins, Minerals & Supplements (VMS)

  • Analgesics

  • Dermatology

These products are manufactured in various dosage forms such as injectables, tablets, capsules, liquid orals, and ointments, developed through in-house R&D and strategic acquisitions.

Manufacturing & Capabilities

The Company operates six state-of-the-art manufacturing facilities in Hyderabad, Telangana, including:

  • Two dedicated injectable facilities

  • One solid oral dosage facility

  • One dedicated cephalosporin facility

In the injectables segment, it has sterile manufacturing capabilities for critical care and penicillin-based therapies, offering delivery formats such as dry powder injections, pre-filled syringes, ampoules, and vials.

Global Presence & Scale

  • Presence in 50+ global markets (regulated and semi-regulated)

  • Strong focus on research, innovation, and quality manufacturing

  • Committed to improving patient outcomes through advanced pharmaceutical solutions

Strength

Diversified formulations portfolio with strong track record: The company operates across multiple therapeutic segments and dosage forms, reducing dependence on a single product category.

Strategically located and accredited manufacturing facilities: Presence of WHO-GMP and international accreditations like TGA and PIC/S enhances credibility and enables access to regulated export markets.

Strong focus on CDMO business: The company’s CDMO capabilities provide opportunities for long-term contracts, higher margins and global client partnerships.

Risk Factors

Geographical concentration of manufacturing units: Facilities are primarily located in Telangana and Andhra Pradesh, exposing operations to regional disruptions or regulatory changes.

Dependence on injectable segment: A significant portion of revenue is derived from injectable products, making the company vulnerable to demand fluctuations in this segment.

Regulatory compliance risk: Manufacturing facilities are subject to inspections and audits; any adverse observations may impact operations, reputation and financial performance.

Login to view

Login

Sai Parenteral's Latest Announcements

Date Subject Attachment Text Pdf
*Source NSE/BSE

Login to view

Login

Sai Parenteral's Financial Results

*Source NSE/BSE

Sai Parenteral's Lead Manager(s)

Sai Parenteral's Address

Sai Parenteral's Ltd.
Address
Plot No 39
5th floor, Lavanya Arcade Jayabheri Enclave
Gachibowli, K.V.Rangareddy, Seri Lingampally
Hyderabad, Telangana, 500032
Phone: +91 79979 91301
E-mail: cs@saiparenterals.com
Website: https://www.saiparenterals.com/

Sai Parenteral's Registrar

Bigshare Services Pvt Ltd

+912262638200

ipo@bigshareonline.com

https://ipo.bigshareonline.com/IPO_Status.html

Bigshare Services Pvt Ltd 1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis,Makwana Road, Marol, Andheri(E), Mumbai - 400 059

Sai Parenteral's Reviewers

Reviewer Recommendation File
Ashika Research Apply
SBICAP Securities Limited May Apply
Capital Market Avoid
Swastika Investmart Ltd Avoid
Axis Capital Limited Not Rated
Pioneer Investcorp Ltd. (PINC) Not Rated